D K Lei1, M Yousaf1, S R Janmohamed1, P P Vakharia2, R Chopra3, R Sacotte4, K R Patel5, V Singam6, S Immaneni1, R Kantor3, D Y Hsu1, J I Silverberg1,7. 1. Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 2. Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA. 3. State University of New York Downstate Medical Center, Brooklyn, NY, USA. 4. Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA. 5. Department of Internal Medicine, Massachusetts General Hospital, Boston, MA, USA. 6. Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL, USA. 7. Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Abstract
BACKGROUND: Sleep disturbances are common in adults with atopic dermatitis (AD). Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance (SD) and Sleep-Related Impairment (SRI) are validated questionnaires to assess sleep in adults. Little is known about their measurement properties in adults with AD. OBJECTIVES: To assess the measurement properties of the PROMIS SD and SRI eight-item short forms in AD. METHODS: We performed a prospective dermatology-practice-based study using questionnaires and evaluation by a dermatologist (n = 420). RESULTS: PROMIS SD and SRI showed moderate correlations to each other (ρ = 0·67), and weak correlations with Patient-Oriented Eczema Measure (ρ = 0·43 and 0·39, respectively); average (ρ = 0·31/0·30) and worst numerical rating scale for itch (ρ = 0·32/0·30); Eczema Area and Severity Index (ρ = 0·41/0·31); and Scoring Atopic Dermatitis (SCORAD) (ρ = 0·44/0·30) (Spearman correlations, P < 0·001). PROMIS SD and SRI increased significantly and stepwise with more frequent sleep disturbance, severe itch and self-reported global AD severity (ancova, P < 0·001). PROMIS SD and SRI showed good internal consistency (Cronbach alpha 0·84 and 0·91). Changes from baseline in PROMIS SD and SRI were weakly to moderately correlated with each other and with changes of multiple patient-reported and clinician-reported AD outcomes. There were no floor or ceiling effects for PROMIS SD or SRI. The median completion time for PROMIS SD and SRI was 2 min. CONCLUSIONS: PROMIS SD and SRI showed good construct validity, internal consistency, responsiveness and feasibility to assess sleep in adult patients with AD. What is already known about this topic? The Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance (SD) and Sleep-Related Impairment (SRI) scales were found to be valid in adults with chronic disease. However, the validity and feasibility of PROMIS SD and SRI in atopic dermatitis remain unknown. What does this study add? This study demonstrated that PROMIS SD and SRI had good content, concurrent, convergent and discriminant validity; feasibility; and responsiveness, with no floor or ceiling effects observed. What are the clinical implications of this work? The PROMIS SD and SRI eight-item bank short forms appear to have sufficient validity and feasibility to be used as assessments for burden of sleep in adults with atopic dermatitis in clinical practice.
BACKGROUND: Sleep disturbances are common in adults with atopic dermatitis (AD). Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance (SD) and Sleep-Related Impairment (SRI) are validated questionnaires to assess sleep in adults. Little is known about their measurement properties in adults with AD. OBJECTIVES: To assess the measurement properties of the PROMIS SD and SRI eight-item short forms in AD. METHODS: We performed a prospective dermatology-practice-based study using questionnaires and evaluation by a dermatologist (n = 420). RESULTS: PROMIS SD and SRI showed moderate correlations to each other (ρ = 0·67), and weak correlations with Patient-Oriented Eczema Measure (ρ = 0·43 and 0·39, respectively); average (ρ = 0·31/0·30) and worst numerical rating scale for itch (ρ = 0·32/0·30); Eczema Area and Severity Index (ρ = 0·41/0·31); and Scoring Atopic Dermatitis (SCORAD) (ρ = 0·44/0·30) (Spearman correlations, P < 0·001). PROMIS SD and SRI increased significantly and stepwise with more frequent sleep disturbance, severe itch and self-reported global AD severity (ancova, P < 0·001). PROMIS SD and SRI showed good internal consistency (Cronbach alpha 0·84 and 0·91). Changes from baseline in PROMIS SD and SRI were weakly to moderately correlated with each other and with changes of multiple patient-reported and clinician-reported AD outcomes. There were no floor or ceiling effects for PROMIS SD or SRI. The median completion time for PROMIS SD and SRI was 2 min. CONCLUSIONS: PROMIS SD and SRI showed good construct validity, internal consistency, responsiveness and feasibility to assess sleep in adult patients with AD. What is already known about this topic? The Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance (SD) and Sleep-Related Impairment (SRI) scales were found to be valid in adults with chronic disease. However, the validity and feasibility of PROMIS SD and SRI in atopic dermatitis remain unknown. What does this study add? This study demonstrated that PROMIS SD and SRI had good content, concurrent, convergent and discriminant validity; feasibility; and responsiveness, with no floor or ceiling effects observed. What are the clinical implications of this work? The PROMIS SD and SRI eight-item bank short forms appear to have sufficient validity and feasibility to be used as assessments for burden of sleep in adults with atopic dermatitis in clinical practice.
Authors: Ruth L Chimenti; Barbara A Rakel; Dana L Dailey; Carol G T Vance; Miriam B Zimmerman; Katharine M Geasland; Jon M Williams; Leslie J Crofford; Kathleen A Sluka Journal: Front Pain Res (Lausanne) Date: 2021-06-08
Authors: Mimi Ton; Nathaniel F Watson; Arthur Sillah; Rachel C Malen; Julia D Labadie; Adriana M Reedy; Stacey A Cohen; Andrea N Burnett-Hartman; Polly A Newcomb; Amanda I Phipps Journal: Cancers (Basel) Date: 2021-05-25 Impact factor: 6.639
Authors: J I Silverberg; D Lei; M Yousaf; S R Janmohamed; P P Vakharia; R Chopra; R Chavda; S Gabriel; K R Patel; V Singam; R Kantor; D Y Hsu Journal: J Eur Acad Dermatol Venereol Date: 2020-09-01 Impact factor: 6.166
Authors: Sarah M Goodday; Emma Karlin; Alexandria Alfarano; Alexa Brooks; Carol Chapman; Rachelle Desille; Shazia Rangwala; Daniel R Karlin; Hoora Emami; Nancy Fugate Woods; Adrien Boch; Luca Foschini; Mackenzie Wildman; Francesca Cormack; Nick Taptiklis; Abhishek Pratap; Marzyeh Ghassemi; Anna Goldenberg; Sujay Nagaraj; Elaine Walsh; Stephen Friend Journal: JMIR Form Res Date: 2021-12-10
Authors: J Puelles; F Fofana; D Rodriguez; J I Silverberg; A Wollenberg; C Dias Barbosa; M Vernon; R Chavda; S Gabriel; C Piketty Journal: Br J Dermatol Date: 2021-11-17 Impact factor: 11.113
Authors: Trisha Kaundinya; Uros Rakita; Armaan Guraya; Donna Maria Abboud; Emily Croce; Jacob P Thyssen; Andrew Alexis; Jonathan I Silverberg Journal: J Invest Dermatol Date: 2021-08-02 Impact factor: 8.551